NXTC
NextCure, Inc.
Next earnings Aug 5, 2026 · consensus $-1.97 EPS
Last earnings -5.0% on 2026-05-07
$1.65
▼ -0.30%$1.65▼ -70.83%
over 1Y
L $1.65EODHDH $14.27
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.3%
1W-6.0%
1M-72.9%
3M-83.6%
YTD-87.6%
1Y-70.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 252.6% YoY; but unprofitable (net margin -249.5%).
Revenue (FY2020) $22.4M · FY2020
NextCure, Inc. shows $22.4M in FY2020 revenue (+252.6% YoY), a -249.5% net margin, and -159.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$70.8M | -$75.9M | -$67.6M | -$59.7M | -$57.6M |
| Net income | -$69.4M | -$74.7M | -$62.7M | -$55.7M | -$55.8M |
| Diluted EPS | -$2.51 | -$2.69 | -$2.25 | -$23.88 | -$19.65 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$18.5M
EV / EBITDA—
EV / Sales-0.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-953.5%
FCF yield-855.2%
Quality & risk
ROIC (est.)-124.3%
Free cash flow-$50.1M
Total debt$1.67M
Net cash$24.3M
Altman Z-Score-14.48 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-87.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-182026-06-25open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-06-012026-06-01open ↗SCHEDULE 13G/AFiling2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗SCHEDULE 13G/AFiling2026-05-06open ↗
Frequently asked
- Is NextCure, Inc. (NXTC) a buy?
- NXTC currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 252.6% YoY; but unprofitable (net margin -249.5%).
- What is NextCure, Inc.'s quality score?
- NXTC scores 58.45098039215686/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001661059, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 8:04:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.